Clinical trials are a critical part of the drug development process. The initiation of a Phase 2-equivalent study for STENDRA indicates that Petros Pharmaceuticals is making progress in its product development, which could potentially boost investor confidence in the company's product pipeline. However, the outcome of the study and its impact on the company's stock price will depend on the results of the trial.